- Home
- GYRE vs SNDX Comparison
GYRE vs SNDX Comparison
Compare GYRE & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- SNDX
- Stock Information
- Founded
- GYRE 2002
- SNDX 2005
- Country
- GYRE United States
- SNDX United States
- Employees
- GYRE N/A
- SNDX N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- GYRE Health Care
- SNDX Health Care
- Exchange
- GYRE Nasdaq
- SNDX Nasdaq
- Market Cap
- GYRE 1.1B
- SNDX 1.1B
- IPO Year
- GYRE N/A
- SNDX 2016
- Fundamental
- Price
- GYRE $10.95
- SNDX $13.08
- Analyst Decision
- GYRE
- SNDX Strong Buy
- Analyst Count
- GYRE 0
- SNDX 10
- Target Price
- GYRE N/A
- SNDX $36.20
- AVG Volume (30 Days)
- GYRE 129.2K
- SNDX 2.6M
- Earning Date
- GYRE 11-13-2024
- SNDX 02-25-2025
- Dividend Yield
- GYRE N/A
- SNDX N/A
- EPS Growth
- GYRE N/A
- SNDX N/A
- EPS
- GYRE N/A
- SNDX N/A
- Revenue
- GYRE $105,033,000.00
- SNDX $16,000,000.00
- Revenue This Year
- GYRE $25.32
- SNDX N/A
- Revenue Next Year
- GYRE $12.95
- SNDX $14.15
- P/E Ratio
- GYRE N/A
- SNDX N/A
- Revenue Growth
- GYRE N/A
- SNDX N/A
- 52 Week Low
- GYRE $8.26
- SNDX $12.06
- 52 Week High
- GYRE $26.37
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- GYRE 48.93
- SNDX 41.29
- Support Level
- GYRE $9.51
- SNDX $12.40
- Resistance Level
- GYRE $11.11
- SNDX $13.16
- Average True Range (ATR)
- GYRE 0.85
- SNDX 0.65
- MACD
- GYRE 0.04
- SNDX 0.10
- Stochastic Oscillator
- GYRE 29.33
- SNDX 39.38
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.